Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $295 | $119 | $161 | $1,706 |
| - Cash | $129 | $125 | $127 | $142 |
| + Debt | $1 | $1 | $1 | $2 |
| Enterprise Value | $166 | -$5 | $36 | $1,566 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$5 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$56 | -$54 | -$71 | -$63 |
| % Margin | – | – | – | – |
| Net Income | -$57 | -$53 | -$68 | -$59 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.35 | -0.33 | -0.42 | -0.37 |
| % Growth | -6.1% | 21.4% | -13.5% | – |
| Operating Cash Flow | -$47 | -$52 | -$59 | -$50 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$47 | -$52 | -$59 | -$50 |